Hematology, transfusion and cell therapy最新文献_第7页

Comparative evaluation of rapid plasma reagin and ELISA with Treponema pallidum hemagglutination assay for the detection of syphilis in blood donors: a single center experience. 在检测献血者梅毒方面，快速血浆试剂和酶联免疫吸附试验与苍白螺旋体血凝试验的比较评估：一个单一中心的经验。

Hematology, transfusion and cell therapy Pub Date : 2024-02-19 DOI: 10.1016/j.htct.2024.01.003

Brinda Kakkar, Joseph Philip, Rajeevinder Singh Mallhi

{"title":"Comparative evaluation of rapid plasma reagin and ELISA with Treponema pallidum hemagglutination assay for the detection of syphilis in blood donors: a single center experience.","authors":"Brinda Kakkar, Joseph Philip, Rajeevinder Singh Mallhi","doi":"10.1016/j.htct.2024.01.003","DOIUrl":"https://doi.org/10.1016/j.htct.2024.01.003","url":null,"abstract":"Introduction: The prime responsibility of blood transfusion services in India is to provide safe blood. The donated blood is tested for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), malaria and syphilis. In India, the screening of donated blood for syphilis is performed by rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL), whereas the World Health Organization (WHO) recommends screening of syphilis in blood donors by enzyme-linked immunosorbent assay (ELISA). Therefore, the aim of this study was to evaluate the performance of RPR and ELISA with the Treponema pallidum hemagglutination assay (TPHA - the gold standard) for the detection of syphilis in blood donors.Methods: In this cross-sectional study, 1524 consecutive whole blood donors were screened from April to October 2022. All blood samples collected during the study period were tested by RPR, ELISA and the TPHA and the results obtained were compared.Results: The seroprevalence of syphilis in blood donors in this study was 0.06% by RPR and 0.72% by ELISA and TPHA. On considering ELISA and the TPHA as the gold standard, ELISA had comparable sensitivity (100%), a higher specificity (100% vs. 99.34%), a higher positive predictive value (PPV - 100% vs. 9.1%) and no biological false positive/false negative results (0 vs. 10 false negatives) when compared to RPR.Conclusion: ELISA performed better as a screening assay than RPR in the detection of syphilis in blood donors, which is in agreement with the WHO recommendations for syphilis testing in blood donors with low prevalence.","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140013800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric autoimmune hemolytic anemia: A single-center retrospective study. 小儿自身免疫性溶血性贫血：单中心回顾性研究

Hematology, transfusion and cell therapy Pub Date : 2024-02-19 DOI: 10.1016/j.htct.2023.12.006

Aline Sayuri Sakamoto, Fernanda Silva Sequeira, Bruna Paccola Blanco, Marlene Pereira Garanito

{"title":"Pediatric autoimmune hemolytic anemia: A single-center retrospective study.","authors":"Aline Sayuri Sakamoto, Fernanda Silva Sequeira, Bruna Paccola Blanco, Marlene Pereira Garanito","doi":"10.1016/j.htct.2023.12.006","DOIUrl":"https://doi.org/10.1016/j.htct.2023.12.006","url":null,"abstract":"Background: Autoimmune hemolytic anemia (AIHA) is a rare, life-threatening disease in pediatrics. This article describes the clinical features, diagnostic workup, treatment and outcome in patients with AIHA.Method: Medical charts of under 18-year-old patients with AIHA treated at a tertiary Brazilian institution from 2006 to 2021 were retrospectively reviewed. Data analysis was primarily descriptive, using medians, interquartile ranges, and categorical variables presented as absolute frequencies.Main results: Twenty-four patients (14 female, 10 male) were evaluated in this study. The median age at diagnosis was 5.99 years (range: 0.25-17.1 years) and the median hemoglobin level was 4.85 g/dL (range: 4.17-5.57 g/dL). Most had warm antibodies (83.3 %). Twelve patients (50 %) had known underlining diseases, four (16.6 %) presented with AIHA concomitant with acute infectious diseases and three (12.5 %) had an undetermined post-vaccine association. Steroids and intravenous immunoglobulin were first-line therapy in 23 cases. Seven patients (29.1 %) required second and third-line treatments (rituximab, cyclophosphamide and splenectomy). The median follow-up period was 4.4 years (range: 1.0-6.7 years). Thirteen patients (54.1 %) were discharged, five cases (20.8 %) were lost to follow-up and no patient died. The median age for the six remaining patients was 11.53 years (8.5-14.7) with all of them having complete responses with no further therapies.Conclusion: Most cases of AIHA are secondary to an underlying systemic disease or have a possible correlation with infections/vaccines and respond to steroids. The second and third-line therapies for refractory and relapse cases remain a dilemma. A prospective, multicenter study is essential to address the best therapeutic combinations.","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139944811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction. 利用数字液滴聚合酶链反应定量检测 BCR::ABL1 的 T315I 突变。

Hematology, transfusion and cell therapy Pub Date : 2024-02-17 DOI: 10.1016/j.htct.2023.12.007

Huijun Mu, Jian Zou, Haiping Zhang

{"title":"Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction.","authors":"Huijun Mu, Jian Zou, Haiping Zhang","doi":"10.1016/j.htct.2023.12.007","DOIUrl":"https://doi.org/10.1016/j.htct.2023.12.007","url":null,"abstract":"Background: T315I mutations of the BCR::ABL1 gene lead to resistance to tyrosine kinase inhibitors (TKIs). This study evaluated the performance of digital droplet polymerase chain reaction (ddPCR) in quantifying T315I mutations and their frequency in Philadelphia chromosome (Ph) positive hematological patients.Methods: The course of disease and BCR::ABL1 fusion transcripts (e13a2, e14a2 and e1a2) were retrospectively reviewed in 21 patients with acute lymphoblastic leukemia (ALL) and 85 patients with chronic myeloid leukemia (CML). T315I mutation analysis was carried out using ddPCR and the limit of detection was assessed using mutant T315I DNA at varying variant allele fractions.Results: T315I mutations were found in two ALL patients and one CML patient without remission in molecular biology and with mutation burdens of 29.20%, 40.85%, and 3.00%, respectively. The mutation burden of ALL patients was higher than that of CML patients, but there was no significant difference between the two (p-value = 0.0536). The test's limit of detection was 0.02% with a correlation coefficient greater than 0.99 between the expected and actual detection abundances.Conclusion: T315I mutations have a high incidence in Ph-positive ALL patients even if the course of disease is short. In molecular biology, T315I mutation detection is indicated for CML patients not in remission.","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139934768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of hydroxyurea on tubular phosphate handling in sickle cell nephropathy 羟基脲对镰状细胞肾病患者肾小管磷酸盐处理的影响

Hematology, transfusion and cell therapy Pub Date : 2024-02-01 DOI: 10.1016/j.htct.2023.11.015

Gabriela Araujo de Abreu, Duaran Lopes de Sousa, Suzzy Maria Carvalho Dantas, Alice Maria Costa Martins, T. L. Sampaio, R. Lemes

引用次数: 0

Influence of hydroxyurea on tubular phosphate handling in sickle cell nephropathy 羟基脲对镰状细胞肾病患者肾小管磷酸盐处理的影响

Hematology, transfusion and cell therapy Pub Date : 2024-02-01 DOI: 10.1016/j.htct.2023.11.015

Gabriela Araujo de Abreu, Duaran Lopes de Sousa, Suzzy Maria Carvalho Dantas, Alice Maria Costa Martins, T. L. Sampaio, R. Lemes

引用次数: 0

HLA-DR-DQ associations, combined with PLASMIC score, are reliable predictors of acquired thrombotic thrombocytopenic purpura (aTTP) and aid in differentiating aTTP from other thrombotic microangiopathies HLA-DR-DQ 关联与 PLASMIC 评分相结合，是获得性血栓性血小板减少性紫癜（aTTP）的可靠预测指标，有助于区分 aTTP 和其他血栓性微血管病

Hematology, transfusion and cell therapy Pub Date : 2024-02-01 DOI: 10.1016/j.htct.2023.11.016

Soumya Pandey, Akul Shrivastava, Y. Harville, Michele Cottler-Fox, T. Harville

引用次数: 0

HLA-DR-DQ associations, combined with PLASMIC score, are reliable predictors of acquired thrombotic thrombocytopenic purpura (aTTP) and aid in differentiating aTTP from other thrombotic microangiopathies HLA-DR-DQ 关联与 PLASMIC 评分相结合，是获得性血栓性血小板减少性紫癜（aTTP）的可靠预测指标，有助于区分 aTTP 和其他血栓性微血管病

Hematology, transfusion and cell therapy Pub Date : 2024-02-01 DOI: 10.1016/j.htct.2023.11.016

Soumya Pandey, Akul Shrivastava, Y. Harville, Michele Cottler-Fox, T. Harville

引用次数: 0

Anti-PF4 antibodies and their relationship with COVID infection 抗 PF4 抗体及其与 COVID 感染的关系

Hematology, transfusion and cell therapy Pub Date : 2024-02-01 DOI: 10.1016/j.htct.2023.11.012

Chieh Yang, Irene Wang, Akshit Chitkara, Jibin Swankutty, Rushin Patel, Samir V Kubba

引用次数: 0

Hemorrhagic code protocol, a successful case in the patient blood management model for patients with severe hemorrhages 出血代码协议--严重出血患者血液管理模式的成功案例

Hematology, transfusion and cell therapy Pub Date : 2024-02-01 DOI: 10.1016/j.htct.2024.01.002

João Carlos de Campos Guerra, Michele Jaures, Roseny dos Reis Rodrigues, A. Cypriano, D. Malheiro, Anna Carolina Batista Dantas, Fernanda Paulino Fernandes, Neila Maria Marques Negrini, V. Teich

引用次数: 0

Epidemiology, patient journey and unmet needs related to hemophilia in Brazil: a scoping review with evidence map 巴西与血友病有关的流行病学、患者历程和未满足的需求：附有证据地图的范围界定审查

Hematology, transfusion and cell therapy Pub Date : 2024-02-01 DOI: 10.1016/j.htct.2023.12.004

N. B. Schneider, C. L. P. de Araujo, Harryson Wings Godoy dos Santos, Simone Lima, Maicon Falavigna, D. Pachito

引用次数: 0